Trial · NCT01962870
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment. | Baseline; Week 4 | Social Responsiveness Scale, 2nd Edition (SRS) scores measure social abilities with lower scores meaning better social abilities. (T-Score Range: 37- above 90 ) |
| Secondary | Change From Baseline in Clinical Global Impression (CGI) Severity, Social and Communication Scores During Treatment. | Baseline; Week 4 | Higher Scores on the CGI severity scale mean more greater social and communication deficits (Range 1-7) |
| Secondary | Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment. | Baseline; Week 4 | Higher scores mean better ability to read emotions and lower scores mean worse ability to read emotions. Range 0-28. |
| Secondary | Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment. | Baseline; Week 4 | Higher scores mean better facial emotion recognition abilities. Lower scores mean worse facial emotion recognition abilities (Range: 0-42). |
| Secondary | Change From Baseline in Parent Rated Repetitive Behavior Scale Revised (RBS-R) Scores During Treatment. | Baseline; Week 4 | Higher scores on the Repetitive Behavior Scale- Revised mean higher levels of repetitive and restricted behaviors. (Raw Score Total Range: 0 - 129) |
| Secondary | Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment. | Baseline; Week 4 | Scale measuring severity of anxiety symptoms. Higher scores mean higher levels of anxiety, lower scores mean lower levels of anxiety. (Raw Score Range: 0 - 114) |
| Secondary | Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment | Baseline through Week 4 | Dosage Record Treatment Emergent Symptom Scale (DOTES) side effects reported by parents during 4-weeks of treatment. Participant Counts are used. |
| Secondary | Change From Baseline on the Overt Aggression Scale (OAS) During Treatment. | Baseline through Week 4 | Count of participants reporting an increase of aggression during treatment compared to baseline (pretreatment). |
| Secondary | Change From Baseline in Heart Rate After Treatment. | Baseline; Week 4 | Sitting heart rate (beats per minute). |
| Secondary | Change From Baseline in Parent Rated Aberrant Behavior Checklist (ABC) Scores During Treatment. | Baseline; Week 4 | Higher scores indicate more symptoms, lower scores indicate fewer symptoms. Irritability scores can range from 0-45. Lethargy scores can range from 0-48. Stereotypy scores can range from 0-21. Hyperactivity scores can range from 0-48. Inappropriate speech scores can from 0-12. |
| Secondary | Change From Baseline in Parent Rated Pediatric Quality of Life (PedQL) Inventory Scores During Treatment. | Baseline; Week 4 | Higher scores mean better quality of life and lower scores mean worse quality of life (Range: Minimum=0; Maximum=100). |
| Secondary | Change From Baseline in Parent Rated Vineland Adaptive Behavior Scales Second Edition (VABS-II) - Social and Communication Subscales During Treatment. | Baseline; Week 4 | Higher Social Standard Score means better social skills, lower Social Standard Score means worse social skills. Higher Communication Standard Score means better communication skills, lower Communication Standard Score means worse communication skills. Standard Scores can range from 20 to 160. |
| Secondary | Change From Baseline in Clinical Chemistry Labs (NA+, K+, Cl-) During Treatment. | Baseline; Week 4 | Clinical chemistry labs(sodium, potassium, chloride) |
| Secondary | Change From Baseline in Laboratory Based Eye-gaze to Social Cues During Treatment. | Baseline; Week 4 | |
| Secondary | Change From Baseline in Laboratory Based Social Mimicry Abilities During Treatment. | Baseline; Week 4 | |
| Secondary | Change From Baseline in Blood Pressure After Treatment | Baseline; Week 4 | Sitting Systolic and Diastolic blood pressure. |
| Secondary | Change From Baseline in Body Weight After Treatment. | Baseline; Week 4 | |
| Secondary | Change From Baseline in Body Temperature After Treatment | Baseline; Week 4 | |
| Secondary | Change From Baseline in the Awareness of Social Inference Test Revised (TASIT-R) Scores During Treatment. | Baseline, Week 4 | |
| Secondary | Change From Baseline in a Developmental Neuropsychological Assessment, Second Edition. (NEPSY-II) Affect Recognition Scores During Treatment. | Baseline; Week 4 | Higher Affect Recognition scores mean better affect recognition abilities, lower Affect Recognition scores mean worse affect recognition abilities. Scores can range from 1 to 19. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01962870/registered